DiaSorin S.p.A. (LON:0GZX)

Market Cap	4.26B
Revenue (ttm)	1.01B
Net Income (ttm)	162.38M
Shares Out	n/a
EPS (ttm)	3.01
PE Ratio	26.25
Forward PE	20.21
Dividend	1.01 (1.11%)
Ex-Dividend Date	May 19, 2025

Volume	10,139
Average Volume	7,752
Open	90.85
Previous Close	90.94
Day's Range	90.47 - 91.76
52-Week Range	76.24 - 112.10
Beta	0.25
RSI	53.24
Earnings Date	Jul 31, 2025

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR